Literature DB >> 9872990

Activation of a CrkL-stat5 signaling complex by type I interferons.

E N Fish1, S Uddin, M Korkmaz, B Majchrzak, B J Druker, L C Platanias.   

Abstract

Type I interferons (IFNalpha and IFNbeta) transduce signals by inducing tyrosine phosphorylation of Jaks and Stats, as well as the CrkL adapter, an SH2/SH3-containing protein which provides a link to downstream pathways that mediate growth inhibition. We report that Stat5 interacts constitutively with the IFN receptor-associated Tyk-2 kinase, and during IFNalpha stimulation its tyrosine-phosphorylated form acts as a docking site for the SH2 domain of CrkL. CrkL and Stat5 then form a complex that translocates to the nucleus. This IFN-inducible CrkL-Stat5 complex binds in vitro to the TTCTAGGAA palindromic element found in the promoters of a subset of IFN-stimulated genes. Thus, during activation of the Type I IFN receptor, CrkL functions as a nuclear adapter protein and, in association with Stat5, regulates gene transcription through DNA binding.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9872990     DOI: 10.1074/jbc.274.2.571

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

Review 1.  The molecular basis for differential type I interferon signaling.

Authors:  Gideon Schreiber
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

2.  STAT5: a Target of Antagonism by Neurotropic Flaviviruses.

Authors:  Matthew G Zimmerman; James R Bowen; Circe E McDonald; Ellen Young; Ralph S Baric; Bali Pulendran; Mehul S Suthar
Journal:  J Virol       Date:  2019-11-13       Impact factor: 5.103

Review 3.  IFNs-signaling effects on lung cancer: an up-to-date pathways-specific review.

Authors:  Vasiliki Galani; Michalis Kastamoulas; Anna Varouktsi; Evangeli Lampri; Antigoni Mitselou; Dimitrios L Arvanitis
Journal:  Clin Exp Med       Date:  2016-07-14       Impact factor: 3.984

4.  A unique ISRE, in the TATA-less human Isg20 promoter, confers IRF-1-mediated responsiveness to both interferon type I and type II.

Authors:  C Gongora; G Degols; L Espert; T D Hua; N Mechti
Journal:  Nucleic Acids Res       Date:  2000-06-15       Impact factor: 16.971

5.  CrkL is a co-activator of estrogen receptor alpha that enhances tumorigenic potential in cancer.

Authors:  Renjini Ambika Padmanabhan; Lini Nirmala; Megha Murali; Malini Laloraya
Journal:  Mol Endocrinol       Date:  2011-06-23

6.  Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.

Authors:  Simrit Parmar; Jessica Smith; Antonella Sassano; Shahab Uddin; Efstratios Katsoulidis; Beata Majchrzak; Suman Kambhampati; Elizabeth A Eklund; Martin S Tallman; Eleanor N Fish; Leonidas C Platanias
Journal:  Blood       Date:  2005-03-24       Impact factor: 22.113

Review 7.  Immunomodulatory cytokines as therapeutic agents for melanoma.

Authors:  Courtney Nicholas; Gregory B Lesinski
Journal:  Immunotherapy       Date:  2011-05       Impact factor: 4.196

8.  CrkII transgene induces atypical mammary gland development and tumorigenesis.

Authors:  Kelly E Fathers; Sonia Rodrigues; Dongmei Zuo; Indrani Vasudeva Murthy; Michael Hallett; Robert Cardiff; Morag Park
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

9.  Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells.

Authors:  Efstratios Katsoulidis; Antonella Sassano; Beata Majchrzak-Kita; Nathalie Carayol; Patrick Yoon; Alison Jordan; Brian J Druker; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2008-02-20       Impact factor: 5.157

10.  Differential expression of interferon (IFN) regulatory factors and IFN-stimulated genes at early times after West Nile virus infection of mouse embryo fibroblasts.

Authors:  Svetlana V Scherbik; Bronislava M Stockman; Margo A Brinton
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.